Stock Events

Stock Events

Medexus Pharmaceuticals 

$2.51
17
+$0.13+5.66% Thursday 19:52

Statistics

Day High
2.52
Day Low
2.42
52W High
2.62
52W Low
1.43
Volume
1,800
Avg. Volume
10,911
Mkt Cap
81.48M
P/E Ratio
97.9
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JunExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.09
-0.04
0.01
0.05
Expected EPS
-0.0185928685
Actual EPS
N/A

Financials

2.07%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
216.66MRevenue
4.49MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MEDXF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Jazz Pharmaceuticals
JAZZ
Mkt Cap8.35B
Jazz Pharmaceuticals has a diverse portfolio in areas like oncology and pain management, overlapping with Medexus's treatment offerings.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the immunology and oncology sectors, directly challenging Medexus's product lines.
AMGEN
AMGN
Mkt Cap160.66B
Amgen's focus on biologics in areas like rheumatology and oncology puts it in direct competition with Medexus's treatments.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad product range that includes treatments in areas competing with Medexus, such as rheumatology.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb's involvement in immunology and oncology treatments makes it a competitor to Medexus's product offerings.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences' focus on innovative therapies in areas like oncology and inflammatory diseases competes with Medexus's portfolio.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, known for its innovative biologics in areas like immunology, competes with Medexus's therapeutic areas.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk's products in chronic disease management, such as hemophilia treatments, place it in competition with Medexus.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals' focus on serious chronic diseases, including cystic fibrosis, competes with Medexus's approach to chronic conditions.

About

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
Show more...
CEO
Mr. Kenneth d'Entremont
Employees
82
Country
CA
ISIN
CA58410Q2036

Listings

F
DE
P731.F
TO
CA
MDP.TO
OTC Link
US
MEDXF

0 Comments

Share your thoughts

FAQ

What is Medexus Pharmaceuticals stock price today?▼
The current price of MEDXF is $2.51 USD — it has increased by +5.66% in the past 24 hours. Watch Medexus Pharmaceuticals stock price performance more closely on the chart.
What is Medexus Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Medexus Pharmaceuticals stocks are traded under the ticker MEDXF.
Is Medexus Pharmaceuticals stock price growing?▼
MEDXF stock has risen by +10.88% compared to the previous week, the month change is a +8.41% rise, over the last year Medexus Pharmaceuticals has showed a +65.3% increase.
What is Medexus Pharmaceuticals market cap?▼
Today Medexus Pharmaceuticals has the market capitalization of 81.48M
When is the next Medexus Pharmaceuticals earnings date?▼
Medexus Pharmaceuticals is going to release the next earnings report on June 30, 2026.
What were Medexus Pharmaceuticals earnings last quarter?▼
MEDXF earnings for the last quarter are 0 USD per share, whereas the estimation was -0.02 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Medexus Pharmaceuticals revenue for the last year?▼
Medexus Pharmaceuticals revenue for the last year amounts to 216.66M USD.
What is Medexus Pharmaceuticals net income for the last year?▼
MEDXF net income for the last year is 4.49M USD.
How many employees does Medexus Pharmaceuticals have?▼
As of April 05, 2026, the company has 82 employees.
In which sector is Medexus Pharmaceuticals located?▼
Medexus Pharmaceuticals operates in the Health Care sector.
When did Medexus Pharmaceuticals complete a stock split?▼
The last stock split for Medexus Pharmaceuticals was on December 19, 2018 with a ratio of 1:15.
Where is Medexus Pharmaceuticals headquartered?▼
Medexus Pharmaceuticals is headquartered in Toronto, CA.